PTC Therapeutics, Inc.
NASDAQ:PTCTBiotechnology
+$0.60 today
- Market cap
- $5.03B
- Beta
- 0.55
- P/E (TTM)
- -35.0
- EPS (TTM)
- -$2.26
Volume 0.64M
Average 1.27M
PTCT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
PTC Therapeutics, Inc.NASDAQ: PTCT
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $99.15M fell 12.2% year over year, ahead of the -14.7% change in trailing-twelve-month research & development. Sequentially, it fell 1.7% from the prior quarter. Over 3 fiscal years it compounded at -11.3% a year.
Context
- Research & development amounted to 26.3% of revenue in FY2025, down 39.9 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -12.2% holds above the trailing-twelve-month pace of -14.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 455.25M USD
- Year-over-year change
- -14.8%
- 4-year CAGR
- -4.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 455.25M | -14.8% |
| FY2024 | 2024-12-31 | 534.48M | -19.8% |
| FY2023 | 2023-12-31 | 666.56M | +2.3% |
| FY2022 | 2022-12-31 | 651.5M | +20.5% |
| FY2021 | 2021-12-31 | 540.68M | — |
Research & Development vs competitors
How PTCT compares with its peers on the latest reported figures
- PTCT's LTM Jun 2026 research & development of $433.31M is the 7th highest of the 11 companies compared; the peer median is $488.33M.
- Its year-over-year change of -14.7% is the 10th highest of 11, against a peer median of +13.1%.
- Research & development amounts to 43.0% of revenue for PTCT, versus a peer median of 74.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $181.1B | +19955.1% | +12.4% | 17.6% | |
| LTM Sep 2026 | $923.16M | +4.7% | +3.2% | 96.2% | |
| LTM Mar 2026 | $902.58M | -34.5% | +20.2% | 41.3% | |
| LTM Mar 2026 | $770.95M | +12.5% | +2.0% | 115.2% | |
| LTM Jun 2026 | $530.96M | +12.1% | +6.1% | 74.5% | |
| LTM Jun 2026 | $445.71M | +17.2% | +40.8% | — | |
| LTM Jun 2026 | $433.31M | -14.7% | -11.3% | 43.0% | |
| LTM Mar 2026 | $189.6M | +13.6% | +16.4% | 264.1% | |
| LTM Mar 2026 | $155.55M | +43.4% | +21.4% | — | |
| LTM Mar 2026 | $92.92M | +60.8% | +57.0% | — | |
| LTM Jun 2026 | $59.23M | +6.3% | +11.0% | 13.4% | |
| Peer median (excluding PTCT) | $488.33M | +13.1% | +14.4% | 74.5% | |
Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 538.59M | 698.8M | 937.82M | 806.78M | 1.73B |
| Cost of Revenue | 32.33M | 44.68M | 65.49M | 57.4M | 71.76M |
| Gross Profit | 506.27M | 654.12M | 872.34M | 749.38M | 1.66B |
| Gross Margin | 94.0% | 93.6% | 93.0% | 92.9% | 95.9% |
| Research & Development | 540.68M | 651.5M | 666.56M | 534.48M | 455.25M |
| Selling, General & Admin | 285.77M | 326M | 332.54M | 300.91M | 347.14M |
| Operating Expenses | 880.71M | 1.1B | 1.31B | 1.05B | 802.39M |
| Depreciation & Amortization | 64.13M | 128.84M | 236.59M | 75.66M | 38.82M |
| EBITDA | (368.18M) | (367.78M) | (330.34M) | (120.46M) | 887.66M |
| EBITDA Margin | -68.4% | -52.6% | -35.2% | -14.9% | 51.3% |
| Operating Income | (374.44M) | (447.41M) | (439.5M) | (302.57M) | 856.51M |
| Operating Margin | -69.5% | -64.0% | -46.9% | -37.5% | 49.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 86.02M | 90.87M | 129.18M | 166.99M | 152.23M |
| Other Income / Expenses | (143.9M) | (140.08M) | (256.61M) | (60.55M) | (159.89M) |
| Income Before Tax | (518.34M) | (587.49M) | (696.11M) | (363.12M) | 696.62M |
| Pre-Tax Margin | -96.2% | -84.1% | -74.2% | -45.0% | 40.3% |
| Income Tax Expense | 5.56M | (28.47M) | (69.51M) | 176K | 13.98M |
| Net Income | (523.9M) | (559.02M) | (626.6M) | (363.3M) | 682.64M |
| Net Margin | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% |
| EPS (Basic) | (7.43) | (7.79) | (8.37) | (4.73) | 8.58 |
| EPS (Diluted) | (7.43) | (7.79) | (8.37) | (4.73) | 7.78 |
| Weighted Avg Shares | 70.47M | 71.73M | 74.84M | 76.85M | 79.53M |
| Weighted Avg Shares (Diluted) | 70.47M | 71.73M | 74.84M | 76.85M | 88.31M |
PTC Therapeutics, Inc.
NASDAQ:PTCT
Intrinsic Alpha fair value
Locked
Current Price
$60.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.